1. Home
  2. LMAT vs AGIO Comparison

LMAT vs AGIO Comparison

Compare LMAT & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$94.30

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$36.97

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMAT
AGIO
Founded
1983
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.2B
IPO Year
2006
2013

Fundamental Metrics

Financial Performance
Metric
LMAT
AGIO
Price
$94.30
$36.97
Analyst Decision
Buy
Buy
Analyst Count
5
8
Target Price
$105.80
$38.88
AVG Volume (30 Days)
292.9K
1.0M
Earning Date
05-05-2026
04-29-2026
Dividend Yield
0.93%
N/A
EPS Growth
30.57
N/A
EPS
0.68
N/A
Revenue
$249,602,000.00
$43,011,000.00
Revenue This Year
$14.21
$76.75
Revenue Next Year
$8.88
$170.73
P/E Ratio
$138.13
N/A
Revenue Growth
13.53
N/A
52 Week Low
$79.01
$22.24
52 Week High
$118.01
$46.00

Technical Indicators

Market Signals
Indicator
LMAT
AGIO
Relative Strength Index (RSI) 47.80 76.71
Support Level $82.26 $36.43
Resistance Level $97.83 $43.72
Average True Range (ATR) 3.02 1.48
MACD 0.63 0.74
Stochastic Oscillator 61.26 95.39

Price Performance

Historical Comparison
LMAT
AGIO

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: